Medtronic plc (MDT) recently announced late-breaking data from the global Lead Evaluation for Defibrillation and Reliability (“LEADR”) Pivotal trial at Heart Rhythm 2024. The outcome showed that the investigational OmniaSecure defibrillation lead met its primary safety and effectiveness endpoints, exceeding prespecified performance goals.The trial findings were simultaneously published in the Heart Rhythm journal. The development is likely to boost Medtronic’s Cardiac Rhythm Management business within the C ...

Key PointsMedtronic had another solid quarter, with FCF expanding to support healthy dividend growth. The guidance is favorable and includes another year of steady, stable growth. Analysts Hold this stock and see it trading near the low end of the expected range with a possible 15% upside. 5 stocks we like better than MedtronicShares of Medtronic NYSE: MDT are falling following its FQ4 release and guidance, opening up a potential buying opportunity. The question is whether its value, yield, balance sheet an ...

Q4's results exhibited consistent organic revenue growth but it got hit by currency fluctuations and strategic divestitures.Medical technology specialist Medtronic (MDT -5.11%) released fourth-quarter and full-year data for fiscal 2024 on Thursday, May 23, that painted a nuanced financial picture.The company reported $8.59 billion in Q4 revenue which was up less than 1% year over year, yet it rose a robust 5.4% growth on an organic basis (growth not attributable to mergers and acquisitions). Medtronic's bus ...

Medtronic plc (MDT) reported adjusted earnings per share (EPS) of $1.46 in fourth-quarter fiscal 2024, down 7.5% from the year-ago quarter’s figure. The figure beat the Zacks Consensus Estimate by 0.7%.Without certain one-time adjustments — including restructuring and associated costs, amortization and acquisition-related costs, among others — GAAP EPS were 49 cents, down 44.3% from the year-ago quarter’s reported figure.For the full year, adjusted earnings were $5.53 per share, up 4.5% from the year-ago pe ...

A 27x earnings valuation and single-digit growth rate means Medtronic stock is probably going down.Medtronic (MDT -3.43%) stock slipped 2.8% through 10:15 a.m. ET this morning despite beating earnings forecasts in its fiscal Q4 2024 earnings report.Heading into earnings, analysts had the medical devices company pegged for a $1.45 per-share profit, but Medtronic "beat" by a penny, reporting $1.46 instead. Similarly, Medtronic exceeded expectations for $8.4 billion in sales by reporting $8.6 billion.And yet t ...

Medtronic (MDT) reported $8.59 billion in revenue for the quarter ended April 2024, representing a year-over-year increase of 0.5%. EPS of $1.46 for the same period compares to $1.57 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $8.44 billion, representing a surprise of +1.80%. The company delivered an EPS surprise of +0.69%, with the consensus EPS estimate being $1.45.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how th ...

Medtronic (MDT) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.45 per share. This compares to earnings of $1.57 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.69%. A quarter ago, it was expected that this medical device company would post earnings of $1.26 per share when it actually produced earnings of $1.30, delivering a surprise of 3.17%.Over the last four quarters, the co ...

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports full year and fourth quarter fiscal 2024 financial results; announces dividend increase Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Heart; gaining momentum as company enters new product cycles across many high-growth markets DUBLIN – May 23 ...

Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Heart; gaining momentum as company enters new product cycles across many high-growth marketsDUBLIN, May 23, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter (Q4) and fiscal year 2024 (FY24), which ended April 26, 2024.Key HighlightsQ4 revenue of $8.6 billion increased 0.5% as reported and 5.4% organicQ4 GAAP diluted ...

Medtronic plc’s (MDT) most advanced automated insulin delivery (AID) system, MiniMed 780G, was recently recognized by the Fast Company in the Best World-Changing Idea, North America category as part of the 2024 World Changing Ideas Awards. This marks the fourth consecutive year the company has been featured on the list, with previous honors received for GI Genius, the Micra leadless pacemaker and Medtronic LABS.Fast Company's annual World Changing Ideas list celebrates organizations that pursue innovation f ...